Results 61 to 70 of about 281,370 (287)

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]

, 2016
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James, Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Khalil, Hilal S., Langdon, Simon P., Soininen, Tero   +6 more
core   +3 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Joint and individual analysis of breast cancer histologic images and genomic covariates [PDF]

, 2020
A key challenge in modern data analysis is understanding connections between complex and differing modalities of data. For example, two of the main approaches to the study of breast cancer are histopathology (analyzing visual characteristics of tumors ...
Calhoun, Benjamin C., Carmichael, Iain, Couture, Heather D., Geradts, Joseph, Hannig, Jan, Hoadley, Katherine A., Marron, J. S., Niethammer, Marc, Olsson, Linnea, Perou, Charles M., Troester, Melissa A.   +10 more
core   +3 more sources

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade [PDF]

JNCI: Journal of the National Cancer Institute, 2019
Abstract Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with ...
Aleix Prat, Tomás Pascual, Carmine De Angelis, Carolina Gutierrez, Antonio Llombart-Cussac, Tao Wang, Javier Cortés, Brent Rexer, Laia Paré, Andres Forero, Antonio C Wolff, Serafín Morales, Barbara Adamo, Fara Brasó-Maristany, Maria Vidal, Jamunarani Veeraraghavan, Ian Krop, Patricia Galván, Anne C Pavlick, Begoña Bermejo, Miguel Izquierdo, Vanessa Rodrik-Outmezguine, Jorge S Reis-Filho, Susan G Hilsenbeck, Mafalda Oliveira, Maria Vittoria Dieci, Gaia Griguolo, Roberta Fasani, Paolo Nuciforo, Joel S Parker, PierFranco Conte, Rachel Schiff, Valentina Guarneri, C Kent Osborne, Mothaffar F Rimawi   +34 more
openaire   +7 more sources

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines [PDF]

, 2012
Background: Breast cancer is one of the most common cancers among women throughout the world. Therefore, established cell lines are widely used as in vitro experimental models in cancer research.Methods: Two continuous human breast cell lines, designated
Akmal, S.N., Azari, S., Houshmand, M., Jafarzadeh, N., Kamalidehghan, B., Kamalidehghan, F., Rosli, R.   +6 more
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

Breast Cancer: Targets and Therapy, 2023
Qianming Bai,1– 3,* Hong Lv,1– 3,* Longlong Bao,1– 3,* Yu Yang,1– 3 Xin Zhang,4 Heng Chang,1– 3 Tian Xue,1– 3 Min Ren,1– 3 Xiaoli Zhu,1– 3 Xiaoyan Zhou,1– 3,* Wentao Yang1– 3,* 1Department of Pathology, Fudan University Shanghai ...
Bai Q, Lv H, Bao L, Yang Y, Zhang X, Chang H, Xue T, Ren M, Zhu X, Zhou X, Yang W   +10 more
doaj  

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) [PDF]

, 2018
Background: Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines.
Daniels, Benjamin, Girosi, Federico, Houssami, Nehmat, Kiely, Belinda E, Lord, Sarah J, Pearson, Sally-Anne, Tervonen, Hanna   +6 more
core   +2 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source